Elsevier and Conexiant have launched a commercial licensing partnership to distribute 'The Lancet: Research in Context' content across 10 therapeutic areas, deepening the existing relationship between the two organizations.
Elsevier, part of RELX, announced a commercial licensing agreement with Conexiant for The Lancet: Research in Context, launched across 10 therapeutic areas. The deal expands an existing relationship, but no revenue, contract value, or guidance figures are disclosed, so the financial effect on RELX shares is not quantifiable. Conexiant itself is privately held and not tradable.
Elsevier, a division of RELX, has entered a commercial licensing agreement with Conexiant to expand the reach of 'The Lancet: Research in Context'. The initiative, which launched last week, organizes clinical research across 10 specific therapeutic areas to improve engagement for healthcare professionals and life sciences audiences.
The article describes a licensing agreement naming Conexiant as a commercial partner for The Lancet: Research in Context across 10 therapeutic areas, but it gives no financial terms or revenue figures, so any earnings impact cannot be sized from this information.